20/20 Biolabs (NASDAQ:AIDX) Upgraded to Strong-Buy at Maxim Group

Maxim Group upgraded shares of 20/20 Biolabs (NASDAQ:AIDX) to a strong-buy rating in a research note published on Monday morning,Zacks.com reports.

Separately, Wall Street Zen upgraded shares of 20/20 Biolabs to a “hold” rating in a research report on Saturday, March 14th. One analyst has rated the stock with a Strong Buy rating, Based on data from MarketBeat, 20/20 Biolabs presently has an average rating of “Strong Buy” and an average price target of $5.00.

20/20 Biolabs Stock Performance

20/20 Biolabs stock opened at $1.37 on Monday. 20/20 Biolabs has a 1 year low of $1.32 and a 1 year high of $50.00. The business has a 50 day simple moving average of $1.99.

20/20 Biolabs (NASDAQ:AIDX) last posted its quarterly earnings data on Tuesday, March 31st. The company reported ($0.26) earnings per share for the quarter. The business had revenue of $0.54 million for the quarter.

20/20 Biolabs Company Profile

We develop and commercialize AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. We offer two families of lab tests, both under our OneTest brand: (i) OneTest for Cancer, a multi-cancer early detection, or MCED, blood test which has been our primary commercial focus and source of revenues since we wound down our COVID-19 testing business, and (ii) OneTest for Longevity, which measures inflammatory biomarkers, that we expect to launch in the first half of 2026.